Evanthia T Roussos Torres
Overview
Explore the profile of Evanthia T Roussos Torres including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Falcone M, Salhia B, Halbert C, Roussos Torres E, Stewart D, Stern M, et al.
Cancer Res
. 2024 Oct;
84(23):3924-3935.
PMID: 39356624
The striking ethnic and racial disparities in breast cancer mortality are not explained fully by pathologic or clinical features. Structural racism contributes to adverse conditions that promote cancer inequities, but...
2.
Shatsky R, Trivedi M, Yau C, Nanda R, Rugo H, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3737-3747.
PMID: 39277672
Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan...
3.
Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3728-3736.
PMID: 39277671
Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer...
4.
Barbetta A, Bangerth S, Lee J, Rocque B, Roussos Torres E, Kohli R, et al.
Res Sq
. 2024 Jul;
PMID: 39041033
Spatial proteomics enable detailed analysis of tissue at single cell resolution. However, creating reliable segmentation masks and assigning accurate cell phenotypes to discrete cellular phenotypes can be challenging. We introduce...
5.
Iriondo O, Mecenas D, Li Y, Chin C, Thomas A, Moriarty A, et al.
Cancer Res
. 2024 Jul;
84(19):3141-3157.
PMID: 38990731
Hypoxia is a common feature of many solid tumors due to aberrant proliferation and angiogenesis that is associated with tumor progression and metastasis. Most of the well-known hypoxia effects are...
6.
Yang M, Shulkin N, Gonzalez E, Castillo J, Yan C, Zhang K, et al.
bioRxiv
. 2024 Jul;
PMID: 38948812
Solid carcinomas are often highly heterogenous cancers, arising from multiple epithelial cells of origin. Yet, how the cell of origin influences the response of the tumor microenvironment is poorly understood....
7.
Lake K, Colonnetta M, Smith C, Saunders K, Martinez-Algarin K, Mohta S, et al.
Front Cell Dev Biol
. 2024 Jun;
12:1358583.
PMID: 38827528
Breast cancer metastases exhibit many different genetic alterations, including copy number amplifications (CNA). CNA are genetic alterations that are increasingly becoming relevant to breast oncology clinical practice. Here we identify...
8.
Baugh A, Gonzalez E, Narumi V, Kreger J, Liu Y, Rafie C, et al.
Clin Exp Metastasis
. 2024 May;
41(5):733-746.
PMID: 38717519
Metastatic disease results from the dissemination of tumor cells beyond their organ of origin to grow in distant organs and is the primary cause of death in patients with advanced...
9.
Hsu R, Al-Zubeidy B, Flores D, Nazarian A, Baugh A, Gonzalez E, et al.
Breast Cancer Res Treat
. 2024 Apr;
206(2):245-259.
PMID: 38643348
Purpose: Programmed death receptor ligand-1 (PD-L1) expression and tumor mutational burden (TMB) are approved screening biomarkers for immune checkpoint inhibition (ICI) in advanced triple negative breast cancer. We examined these...
10.
Xu L, Saunders K, Huang S, Knutsdottir H, Martinez-Algarin K, Terrazas I, et al.
Cell Rep Med
. 2024 Apr;
5(5):101511.
PMID: 38614094
We present an integrated single-cell RNA sequencing atlas of the primary breast tumor microenvironment (TME) containing 236,363 cells from 119 biopsy samples across eight datasets. In this study, we leverage...